Full Breakdown
Positive Affect Treatment Shows Promise in Restoring Joy for Depression and Anxiety Patients
5/12/2026, 11:59:39 AM
New Therapy Targets Anhedonia in Depression
A randomized controlled trial published in *JAMA Network Open* evaluated Positive Affect Treatment (PAT), a 15-session psychotherapy designed to restore joy, purpose, and reward sensitivity. In a sample of 98 adults with severe anhedonia, major depression, and anxiety, PAT produced greater improvements in overall clinical status than a conventional therapy focused on negative affect. The advantage persisted at a one-month follow-up and was accompanied by significant reductions in depressive and anxiety symptoms.
Background: Anhedonia and Conventional Treatments
Anhedonia—the diminished ability to experience pleasure—affects roughly 90 % of individuals with major depression and is also common in anxiety disorders, PTSD, substance-use disorders, and schizophrenia. Traditional interventions have largely emphasized the reduction of negative emotions, leaving the loss of positive affect largely untreated. Many patients, however, prioritize the recovery of positive feelings over merely alleviating sadness.
Researchers, Institutions, and Funding
The study was led by Alicia E. Meuret and Thomas Ritz of the Anxiety and Depression Research Center at Southern Methodist University, with collaboration from Michelle G. Craske at the University of California, Los Angeles. Additional co-authors include David Rosenfield, Emily Wang, and Christina M. Hough. The research received support from the National Institute of Mental Health (award R61MH115138).
Trial Design and Clinical Outcomes
Participants were randomly assigned to receive either PAT or a standard negative-affect therapy. PAT sessions emphasized reconnecting patients with rewarding activities, shifting attention toward positive experiences, and cultivating habits such as gratitude, savoring, and loving-kindness. Across nine reward-sensitivity measures (covering anticipation, response, and learning) and five threat-processing measures (self-report, behavioral, physiological), six of seven self-reported indices explained the observed clinical improvements. Behavioral and physiological metrics did not show parallel effects.
Data and Statistics
- Sample size: 98 adults
- Intervention length: 15 weekly sessions
- Outcome: Superior overall clinical improvement for PAT vs. control, maintained at 1-month follow-up
- Symptom change: Significant reductions in depression and anxiety scores
- Reward assessment: 9 measures across three domains; self-report data linked to outcomes
- Threat assessment: 5 measures; self-report data linked to outcomes; behavioral/physiological data showed no consistent effect
Why It Matters: Potential Shift in Mental-Health Care
PAT’s focus on enhancing the brain’s “positive system” suggests a therapeutic pathway that complements, rather than replaces, strategies targeting negative affect. If replicated in larger and more diverse cohorts, the approach could broaden treatment options for patients whose primary concern is the loss of joy, potentially improving long-term recovery and reducing suicide risk associated with anhedonia.
Official Statements & Responses
Meuret emphasized that alleviating negative emotions alone does not resolve anhedonia, noting the need for interventions that ask whether activities are meaningful, generate joy, and foster connection. She highlighted the distinction between feeling helpless—where motivation remains—and feeling hopeless, which characterizes severe anhedonia.
Criticism & Opposition
The source material does not present external criticism or dissenting viewpoints. The authors acknowledge that behavioral and physiological measures did not mirror self-report findings, indicating a need for further validation.
Conflicting Reports & Gaps
A discrepancy exists between self-reported improvements in reward and threat processing and the lack of corresponding changes in objective behavioral and physiological assessments. This gap underscores the importance of multimodal outcome tracking in future trials.
Verbatim Quotes
- “Treatment needs to ask: Is this activity meaningful to you? Will it give you joy or a sense of accomplishment? Does it foster connection?” — Alicia E. Meuret, SMU
What’s Next
The research team plans longer-term follow-up assessments to examine durability of PAT effects and intends to explore objective biomarkers that may align self-report and physiological data. Additional randomized trials with larger, more heterogeneous populations are proposed to confirm efficacy and inform clinical guidelines.
